PubRank

Christopher A Ross

Author PubWeight™ 176.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005 6.98
2 Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006 5.32
3 Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005 3.92
4 A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005 3.89
5 Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006 3.57
6 Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci U S A 2002 3.34
7 p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005 3.13
8 Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005 3.00
9 Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry 2002 2.52
10 Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007 2.17
11 Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 2002 2.12
12 A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 2008 2.12
13 Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry 2010 2.11
14 Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol 2008 2.03
15 Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011 1.97
16 Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005 1.92
17 A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet 2003 1.85
18 Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010 1.79
19 "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 2010 1.76
20 Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 2005 1.75
21 Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009 1.73
22 CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A 2009 1.64
23 Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005 1.62
24 Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007 1.61
25 Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem 2008 1.56
26 Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007 1.54
27 Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2010 1.53
28 Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 2009 1.47
29 FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2005 1.46
30 A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 2004 1.45
31 Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 2005 1.43
32 Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002 1.40
33 Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol Brain 2012 1.36
34 Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 2010 1.35
35 Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004 1.34
36 Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 2002 1.33
37 N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 2007 1.31
38 Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet 2006 1.30
39 Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A 2004 1.29
40 Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 2007 1.25
41 A comparison of huntington disease and huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008 1.24
42 The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 2007 1.22
43 Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 2008 1.22
44 Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 2003 1.22
45 Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 2003 1.22
46 Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci U S A 2006 1.20
47 Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 2002 1.20
48 Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum Mol Genet 2008 1.19
49 Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 2006 1.19
50 Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 2004 1.19
51 Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 2010 1.17
52 A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 2005 1.16
53 Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 2009 1.15
54 The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004 1.15
55 Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 2006 1.14
56 A form of DISC1 enriched in nucleus: altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. Proc Natl Acad Sci U S A 2005 1.14
57 Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum Mol Genet 2010 1.12
58 Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum Mol Genet 2004 1.11
59 Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Hum Mol Genet 2002 1.10
60 Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 2011 1.09
61 Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts. Neurobiol Dis 2005 1.08
62 Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. Neuroreport 2004 1.08
63 Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 2013 1.08
64 Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 2012 1.07
65 Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp 2012 1.07
66 Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 2011 1.05
67 Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 2012 1.05
68 Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 2008 1.05
69 Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord 2011 1.05
70 A compact beta model of huntingtin toxicity. J Biol Chem 2011 1.04
71 Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 2005 1.04
72 trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease. J Biol Chem 2012 1.02
73 FXTAS, SCA10, and SCA17 in American patients with movement disorders. Am J Med Genet A 2005 1.01
74 Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 2005 1.01
75 Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004 1.01
76 Dictyostelium huntingtin controls chemotaxis and cytokinesis through the regulation of myosin II phosphorylation. Mol Biol Cell 2011 1.01
77 Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol Dis 2002 1.00
78 Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J Neuropathol Exp Neurol 2005 1.00
79 Transcription meets metabolism in neurodegeneration. Nat Med 2006 0.99
80 Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol Dis 2005 0.99
81 Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 2004 0.99
82 PC12 cell model of inducible expression of mutant DISC1: new evidence for a dominant-negative mechanism of abnormal neuronal differentiation. Neurosci Res 2007 0.99
83 Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiol Aging 2006 0.99
84 Animal models of gene-environment interactions in schizophrenia. Behav Brain Res 2009 0.98
85 Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A 2013 0.98
86 Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord 2012 0.97
87 Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 2003 0.97
88 Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett 2012 0.97
89 Long tandem repeats as a form of genomic copy number variation: structure and length polymorphism of a chromosome 5p repeat in control and schizophrenia populations. Psychiatr Genet 2009 0.96
90 Diagnosis of Huntington disease. Clin Chem 2003 0.95
91 Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem 2013 0.94
92 Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophr Bull 2013 0.94
93 Primate disrupted-in-schizophrenia-1 (DISC1): high divergence of a gene for major mental illnesses in recent evolutionary history. Neurosci Res 2006 0.94
94 Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 2002 0.93
95 Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol 2001 0.93
96 Neuropsychological deficits in Huntington's disease gene carriers and correlates of early "conversion". J Neuropsychiatry Clin Neurosci 2008 0.92
97 Association between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal Huntington Disease. PLoS Curr 2011 0.92
98 Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 2012 0.92
99 Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol Res 2011 0.91
100 Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol 2003 0.91
101 A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol Dis 2007 0.90
102 Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle 2012 0.90
103 Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort. Mov Disord 2012 0.90
104 Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res 2004 0.90
105 Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem 2011 0.90
106 Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 2014 0.90
107 Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. Ann Neurol 2012 0.89
108 Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 2012 0.89
109 Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol 2003 0.88
110 Factors contributing to institutionalization in patients with Huntington's disease. Mov Disord 2011 0.87
111 Severe neurological phenotypes of Q129 DRPLA transgenic mice serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum Mol Genet 2008 0.86
112 Prefrontal executive function associated coupling relates to Huntington's disease stage. Cortex 2013 0.84
113 Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem 2010 0.84
114 Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Hum Genet 2012 0.83
115 LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin. Neurobiol Dis 2012 0.82
116 Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci 2004 0.81
117 Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Res 2012 0.81
118 TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun 2012 0.81
119 Gene expression alterations in bipolar disorder postmortem brains. Bipolar Disord 2013 0.80
120 Potential therapeutic targets for neurodegenerative diseases: lessons learned from calorie restriction. Curr Drug Targets 2010 0.80
121 Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype. Ann Neurol 2002 0.80
122 PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD). Cell Cycle 2015 0.80
123 Frontal cortical synaptic communication is abnormal in Disc1 genetic mouse models of schizophrenia. Schizophr Res 2013 0.80
124 Cognitive impairment and psychiatric symptoms in 133 patients with diseases associated with cerebellar degeneration. J Neuropsychiatry Clin Neurosci 2004 0.79
125 Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging. Neuroimage 2012 0.79
126 Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Mov Disord 2013 0.79
127 Intercellular miscommunication in polyglutamine pathogenesis. Nat Neurosci 2006 0.78
128 ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line. Brain Res 2009 0.78
129 Bioactivity profiling with parallel mass spectrometry reveals an assemblage of green tea metabolites affording protection against human huntingtin and alpha-synuclein toxicity. J Agric Food Chem 2007 0.78
130 Characterization of CTG/CAG repeats on chromosome 18: a study of bipolar disorder. Psychiatr Genet 2005 0.78
131 Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness. Neuropsychopharmacology 2010 0.77
132 Gross feature recognition of Anatomical Images based on Atlas grid (GAIA): Incorporating the local discrepancy between an atlas and a target image to capture the features of anatomic brain MRI. Neuroimage Clin 2013 0.77
133 Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics 2013 0.77
134 Diffuse abnormality of low to moderately organized white matter in schizophrenia. Brain Connect 2011 0.77
135 Huntington's disease: a field on the move. Introduction. Mov Disord 2014 0.76
136 Schizophrenia: A point of disruption. Nature 2009 0.75
137 It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry 2008 0.75